

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets

(11) Publication number:

0 303 506
A3

(12)

EUROPEAN PATENT APPLICATION

(21) Application number: 88307498.1

(51) Int. Cl.⁵: C07D 401/04, A61K 31/445

(22) Date of filing: 12.08.88

(30) Priority: 13.08.87 GB 8719167

(43) Date of publication of application:
15.02.89 Bulletin 89/07(84) Designated Contracting States:
AT BE CH DE ES FR GB GR IT LI LU NL SE(88) Date of deferred publication of the search report:
26.09.90 Bulletin 90/39(71) Applicant: GLAXO GROUP LIMITED
Clarges House 6-12 Clarges Street
London W1Y 8DH(GB)(72) Inventor: Oxford, Alexander William
60 Green Drive

Royston Hertfordshire(GB)

Inventor: Coates, Ian Harold

20 Mandeville Road

Hertfordshire(GB)

Inventor: Butina, Darko


81 High Street

Arlesey, Bedfordshire(GB)

(74) Representative: Kyle, Diana et al
ELKINGTON AND FIFE Beacon House 113
Kingsway
London WC2B 6PP(GB)

(54) Indole derivatives.

(57) Compounds are disclosed of formula (I)



wherein

R₁ represents H or C₁₋₆ alkyl;

R₂ represents H, C₁₋₆ alkyl, C₃₋₇ cycloalkyl, C₃₋₆ alkenyl, phenyl or phen(C₁₋₃)alkyl in which the phenyl ring is optionally substituted by halogen, C₁₋₄ alkoxy, hydroxy or C₁₋₃ alkyl;

R₃ represents H, C₁₋₃ alkyl, -CO₂R₅, -COR₅, -COCO₂R₅ or -CONHR₅ where

R₅ represents H, C₁₋₄ alkyl, C₃₋₇ cycloalkyl, C₂₋₄ alkenyl, aryl or ar(C₁₋₄)alkyl in which the aryl group is optionally substituted by halogen, C₁₋₄ alkoxy, C₁₋₄ alkyl or hydroxy) (provided that where R₃ represents -CO₂R₅, R₅ is other than H);

R₄ represents H, C₁₋₃ alkyl, C₃₋₆ alkenyl, phenyl or phen(C₁₋₃)alkyl;

A-B represents CH-CH₂- or C=CH-

D represents -CO- or -SO₂-

EP 0 303 506 A3

n represents 0, 1-5;

provided that when D represents $-\text{SO}_2$, n is 2, R_3 represents H and R_4 represents H or C_{1-3} alkyl, R_2 is other than H or C_{1-5} alkyl;

and pharmaceutically acceptable salts and solvates (for example hydrates) thereof.

The compounds are indicated as useful for the treatment of migraine, cluster headache, chronic paroxysmal hemicrania and headache associated with vascular disorders.

Processes and intermediates for their preparation and pharmaceutical compositions containing them are also disclosed.



DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl. 4)
A	EP-A-0 200 322 (H. LUNDBECK A/S) * Claims *	1, 11	C 07 D 401/04 A 61 K 31/445
P, X	--- CHEMICAL ABSTRACTS, vol. 109, 1988, pages 14, 15, abstract no. 121996g, Columbus, Ohio, US; E.W. TAYLOR et al.: "Molecular determinants for recognition of RU 24696 analogs at central 5-hydroxytryptamine recognition sites: use of a bilinear function and substituent volumes to describe steric fit", MOL. PHARMACOL. 1988, 34(1), 42-53 * 1H-indole-5-carboxamide, 3-(1,2,3,6-tetrahydro-1-methyl-4-pyridinyl)- (RN 116480-55-8) * -----	1	
			TECHNICAL FIELDS SEARCHED (Int. Cl. 4)
			C 07 D 401/00
The present search report has been drawn up for all claims			
Place of search		Date of completion of the search	Examiner
THE HAGUE		11-07-1990	VAN BIJLEN H.
CATEGORY OF CITED DOCUMENTS			
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons ----- & : member of the same patent family, corresponding document	